Host-directed therapies for antimicrobial resistant respiratory tract infections.
Identifieur interne : 001219 ( Main/Exploration ); précédent : 001218; suivant : 001220Host-directed therapies for antimicrobial resistant respiratory tract infections.
Auteurs : Markus Maeurer [Royaume-Uni] ; Martin Rao ; Alimuddin ZumlaSource :
- Current opinion in pulmonary medicine [ 1531-6971 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- usage thérapeutique : Anti-infectieux.
- Humains, Infections de l'appareil respiratoire, Mucoviscidose, Résultat thérapeutique.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anti-Infective Agents.
- therapy : Respiratory Tract Infections.
- Cystic Fibrosis, Humans, Treatment Outcome.
Abstract
Antimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed.
DOI: 10.1097/MCP.0000000000000271
PubMed: 26989822
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001203
- to stream PubMed, to step Curation: 001203
- to stream PubMed, to step Checkpoint: 001072
- to stream Ncbi, to step Merge: 001538
- to stream Ncbi, to step Curation: 001538
- to stream Ncbi, to step Checkpoint: 001538
- to stream Main, to step Merge: 001223
- to stream Main, to step Curation: 001219
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Host-directed therapies for antimicrobial resistant respiratory tract infections.</title><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation wicri:level="3"><nlm:affiliation>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26989822</idno><idno type="pmid">26989822</idno><idno type="doi">10.1097/MCP.0000000000000271</idno><idno type="wicri:Area/PubMed/Corpus">001203</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001203</idno><idno type="wicri:Area/PubMed/Curation">001203</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001203</idno><idno type="wicri:Area/PubMed/Checkpoint">001072</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001072</idno><idno type="wicri:Area/Ncbi/Merge">001538</idno><idno type="wicri:Area/Ncbi/Curation">001538</idno><idno type="wicri:Area/Ncbi/Checkpoint">001538</idno><idno type="wicri:Area/Main/Merge">001223</idno><idno type="wicri:Area/Main/Curation">001219</idno><idno type="wicri:Area/Main/Exploration">001219</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Host-directed therapies for antimicrobial resistant respiratory tract infections.</title><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation wicri:level="3"><nlm:affiliation>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></author></analytic><series><title level="j">Current opinion in pulmonary medicine</title><idno type="eISSN">1531-6971</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (therapeutic use)</term><term>Cystic Fibrosis</term><term>Humans</term><term>Respiratory Tract Infections (therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-infectieux (usage thérapeutique)</term><term>Humains</term><term>Infections de l'appareil respiratoire ()</term><term>Mucoviscidose</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-infectieux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cystic Fibrosis</term><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Infections de l'appareil respiratoire</term><term>Mucoviscidose</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001219 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001219 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26989822
|texte= Host-directed therapies for antimicrobial resistant respiratory tract infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26989822" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |